Why Aclaris Therapeutics, Inc. (ACRS) stock fell 11.1% intraday on Monday, November 16, 2026
Aclaris Therapeutics, Inc. (ACRS) traded at $3.49 as of 10:31 AM ET, down 11.10% on Monday, November 16, 2026, on volume of 4,375,547 shares (1.5× its 3-month average); market value about $600.0M, according to Nexqual market data (nexqual.com/moves/2026-11-16/ACRS).
ACRS was among the stocks moving 5% or more in an earlier update that day; by the close it was no longer moving that much.
What happened: primary sources
Events Nexqual found for ACRS on Monday, November 16, 2026 or the trading day before (November 13, 2026), each linked to its primary source:
- Nov 16, 2026: SEC 8-K: Other material event source
Quoted from the filing: “Top Line Results The Top Line Results announced were as follows: The Phase 2 trial did not achieve the primary endpoint of percent change from baseline in the Eczema Area and Severity Index score at Week 24 or secondary endpoints. Pharmacodynamic (PD) results showed robust target engagement of TSLP and downregulation of biomarkers related to immune activation including Th1, Th2, and Th17. Bosakitug was generally well tolerated in the trial. ALPHA Trial The Registrant announced that it expects top line results from…”
These are listed as context. A filing or rating change on the same day is not proof that it caused the move; read the source.
More on ACRS
ACRS stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. Other big moves that day: November 16, 2026.
Sources: SEC EDGAR, Nexqual Earnings Flash, analyst rating changes, Nexqual market data. Built November 18, 2026 at 20:48 UTC. Not investment advice.
Data source: Nexqual. Last updated: November 18, 2026 at 20:48 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt